Report overview
Global non invasive cancer diagnostics and technologies market is anticipated to show lucrative growth over the forecast period owing to factor such as rising demand for minimally invasive therapeutics and diagnosis for the treatment of cancer. Moreover, increasing prevalence of cancer because of rising aging population and unhealthy lifestyle is also important factor that is fueling the growth of this market. Commercialization of non invasive cancer diagnostics and technologies is expected to grow owing to completion of human genome project (HGP) which will help in identifying chemical base pairs which make up DNA, hence opening avenues for market players. Rising awareness amongst people about the advantages of early diagnosis and treatment of cancer has led to a hike in number of people undergoing diagnosis. Furthermore, growing research and development in cancer diagnosis and treatment is another factor that is boosting the growth. Advancements in cancer detection technologies like cancer biomarkers and fluorescence in situ hybridization (FISH) technique are also expected to contribute towards the growth of this market.
The global non invasive cancer diagnostics and technologies market is segmented into type and technology. Based on type this market is further sub segmented into breast cancer, blood cancer, lung cancer and solid tumors. Breast cancer held the largest share in 2014 owing to factor such as increasing incidence of breast cancer. Moreover, rising awareness amongst people about symptoms, diagnosis and therapies about breast cancer has contributed towards the dominance of this segment. Also, government and non-government organization?s (NGO) initiatives to create awareness about breast cancer early diagnosis and treatment are also helping to grow this market. Breast cancer segment is also expected to witness lucrative growth over the coming seven years as a consequence of advancements like lumpectomy and partial mastectomy. Based on technology the market is segmented into immunochemistry, molecular diagnosis and clinical chemistry. Molecular diagnostic market held the largest share in 2014 as a consequence of various advantages associated to it. These advantages include high precision of diagnosis such as high specificity, high sensitivity, and rapid turnaround time.
This report aims to provide a comprehensive presentation of the global market for Non-Invasive Cancer Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Invasive Cancer Diagnostics. This report contains market size and forecasts of Non-Invasive Cancer Diagnostics in global, including the following market information:
Global Non-Invasive Cancer Diagnostics Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global top five companies in 2022 (%)
The global Non-Invasive Cancer Diagnostics market was valued at US$ 111670 million in 2022 and is projected to reach US$ 144320 million by 2029, at a CAGR of 3.7% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
CTCs Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Non-Invasive Cancer Diagnostics include Gen-Probe Inc, Digene Corporation, Quest Diagnostics Inc, Cancer, Genetics Inc, BIOVIEW Inc, AVIVA Biosciences Corporation, Laboratory Corporation of America Holdings (LabCorp), A&G Pharmaceutical and Affymetrix Inc, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Non-Invasive Cancer Diagnostics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Non-Invasive Cancer Diagnostics Market, by Type, 2018-2023, 2024-2029 ($ millions)
Global Non-Invasive Cancer Diagnostics Market Segment Percentages, by Type, 2022 (%)
CTCs
CTNAS
Exosomes
Global Non-Invasive Cancer Diagnostics Market, by Application, 2018-2023, 2024-2029 ($ millions)
Global Non-Invasive Cancer Diagnostics Market Segment Percentages, by Application, 2022 (%)
Blood
Urine
Saliva
Global Non-Invasive Cancer Diagnostics Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions)
Global Non-Invasive Cancer Diagnostics Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Non-Invasive Cancer Diagnostics revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Non-Invasive Cancer Diagnostics revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Gen-Probe Inc
Digene Corporation
Quest Diagnostics Inc
Cancer, Genetics Inc
BIOVIEW Inc
AVIVA Biosciences Corporation
Laboratory Corporation of America Holdings (LabCorp)
A&G Pharmaceutical
Affymetrix Inc
Precision Therapeutics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Non-Invasive Cancer Diagnostics, market overview.
Chapter 2: Global Non-Invasive Cancer Diagnostics market size in revenue.
Chapter 3: Detailed analysis of Non-Invasive Cancer Diagnostics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Non-Invasive Cancer Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
